Logo image of ADCT

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

NYSE:ADCT - New York Stock Exchange, Inc. - CH0499880968 - Common Stock - Currency: USD

1.63  -0.04 (-2.4%)

After market: 1.63 0 (0%)

Fundamental Rating

2

Taking everything into account, ADCT scores 2 out of 10 in our fundamental rating. ADCT was compared to 571 industry peers in the Biotechnology industry. ADCT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ADCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADCT has reported negative net income.
In the past year ADCT has reported a negative cash flow from operations.
In the past 5 years ADCT always reported negative net income.
In the past 5 years ADCT always reported negative operating cash flow.
ADCT Yearly Net Income VS EBIT VS OCF VS FCFADCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -105.18%, ADCT is doing worse than 77.44% of the companies in the same industry.
Industry RankSector Rank
ROA -105.18%
ROE N/A
ROIC N/A
ROA(3y)-44.77%
ROA(5y)-53.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADCT Yearly ROA, ROE, ROICADCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100

1.3 Margins

ADCT's Gross Margin of 94.24% is amongst the best of the industry. ADCT outperforms 95.20% of its industry peers.
The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADCT Yearly Profit, Operating, Gross MarginsADCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADCT has been increased compared to 1 year ago.
Compared to 5 years ago, ADCT has more shares outstanding
ADCT has a worse debt/assets ratio than last year.
ADCT Yearly Shares OutstandingADCT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ADCT Yearly Total Debt VS Total AssetsADCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ADCT has an Altman-Z score of -6.92. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.
ADCT has a Altman-Z score of -6.92. This is in the lower half of the industry: ADCT underperforms 68.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.92
ROIC/WACCN/A
WACC6.34%
ADCT Yearly LT Debt VS Equity VS FCFADCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

ADCT has a Current Ratio of 4.92. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
ADCT has a Current ratio (4.92) which is in line with its industry peers.
ADCT has a Quick Ratio of 4.68. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
ADCT has a Quick ratio (4.68) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.92
Quick Ratio 4.68
ADCT Yearly Current Assets VS Current LiabilitesADCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ADCT have decreased by -8.64% in the last year.
The Revenue has been growing slightly by 0.75% in the past year.
ADCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.19% yearly.
EPS 1Y (TTM)-8.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
Revenue 1Y (TTM)0.75%
Revenue growth 3YN/A
Revenue growth 5Y129.19%
Sales Q2Q%27.4%

3.2 Future

The Earnings Per Share is expected to grow by 16.70% on average over the next years. This is quite good.
Based on estimates for the next years, ADCT will show a very strong growth in Revenue. The Revenue will grow by 30.34% on average per year.
EPS Next Y40.62%
EPS Next 2Y21.01%
EPS Next 3Y16.7%
EPS Next 5YN/A
Revenue Next Year6.71%
Revenue Next 2Y8.95%
Revenue Next 3Y18.37%
Revenue Next 5Y30.34%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADCT Yearly Revenue VS EstimatesADCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ADCT Yearly EPS VS EstimatesADCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADCT Price Earnings VS Forward Price EarningsADCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADCT Per share dataADCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ADCT's earnings are expected to grow with 16.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.01%
EPS Next 3Y16.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADC THERAPEUTICS SA

NYSE:ADCT (2/21/2025, 8:04:00 PM)

After market: 1.63 0 (0%)

1.63

-0.04 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners56.97%
Inst Owner Change-96.28%
Ins Owners5.49%
Ins Owner Change4.33%
Market Cap157.60M
Analysts84.62
Price Target8.57 (425.77%)
Short Float %6.73%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.16%
Min EPS beat(2)-4.24%
Max EPS beat(2)18.56%
EPS beat(4)2
Avg EPS beat(4)-21.31%
Min EPS beat(4)-100.76%
Max EPS beat(4)18.56%
EPS beat(8)3
Avg EPS beat(8)-13.77%
EPS beat(12)6
Avg EPS beat(12)-5.28%
EPS beat(16)8
Avg EPS beat(16)-11.91%
Revenue beat(2)0
Avg Revenue beat(2)-5.57%
Min Revenue beat(2)-9.2%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-9.2%
Max Revenue beat(4)7.4%
Revenue beat(8)2
Avg Revenue beat(8)-8.69%
Revenue beat(12)5
Avg Revenue beat(12)2.59%
Revenue beat(16)7
Avg Revenue beat(16)-1.79%
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)1.94%
EPS NQ rev (3m)-8.16%
EPS NY rev (1m)0.08%
EPS NY rev (3m)66.6%
Revenue NQ rev (1m)1.45%
Revenue NQ rev (3m)-1.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS1.28
BVpS-1.78
TBVpS-1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.24%
FCFM N/A
ROA(3y)-44.77%
ROA(5y)-53.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1452.63%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.92
Quick Ratio 4.68
Altman-Z -6.92
F-Score3
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)204.08%
Cap/Depr(5y)174.65%
Cap/Sales(3y)8.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
EPS Next Y40.62%
EPS Next 2Y21.01%
EPS Next 3Y16.7%
EPS Next 5YN/A
Revenue 1Y (TTM)0.75%
Revenue growth 3YN/A
Revenue growth 5Y129.19%
Sales Q2Q%27.4%
Revenue Next Year6.71%
Revenue Next 2Y8.95%
Revenue Next 3Y18.37%
Revenue Next 5Y30.34%
EBIT growth 1Y-93.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.49%
EBIT Next 3Y1.99%
EBIT Next 5YN/A
FCF growth 1Y8.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.7%
OCF growth 3YN/A
OCF growth 5YN/A